Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells
Journal Title: Global Journal of Cancer Therapy - Year 2015, Vol 1, Issue 1
Abstract
Eribulin sensitivity was examined in a panel of twenty-five human cancer cell lines representing a variety of tumor types, with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in sensitivity to eribulin at clinically relevant concentrations. To identify combination drugs capable of increasing anticancer effects in patients already responsive to eribulin, as well as inducing de novo anticancer effects in non-responders, we performed a combinatorial high throughput screen to identify drugs that combine with eribulin to selectively kill tumor cells. Among other observations, we found that inhibitors of ErbB1/ErbB2 (lapatinib, BIBW-2992, erlotinib), MEK (E6201, trametinib), PI3K (BKM-120), mTOR (AZD 8055, everolimus), PI3K/mTOR (BEZ 235), and a BCL2 family antagonist (ABT-263) show combinatorial activity with eribulin. In addition, antagonistic pairings with other agents, such as a topoisomerase I inhibitor (topotecan hydrochloride), an HSP-90 inhibitor (17-DMAG), and gemcitabine and cytarabine, were identified. In summary, the preclinical studies described here have identified several combination drugs that have the potential to either augment or antagonize eribulin’s anticancer activity. Further elucidation of the mechanisms responsible for such interactions may be important for identifying valuable therapeutic partners for eribulin.
Authors and Affiliations
Rickles Richard J, Matsui Junji, Zhu Ping, Funahashi Yasuhiro, Grenier Jill M, Steiger Janine, Zhao Nanding, Littlefield Bruce A, Nomoto Kenichi, Uenaka Toshimitsu
Keywords
Related Articles
- EP ID EP352819
- DOI 10.17352/2581-5407.000004
- Views 86
- Downloads 0
Total Oncology is necessary for Japanese new era
Still in Japan, medical oncologists need to play a main role and work a lot of tasks by themselves in cancer chemotherapy. The situation of cancer chemotherapy has progressed day by day and considering the current enviro...
Is it Time for the Introduction of Colostomy Free Survival in Rectal Cancer Patients
The rectum is considered the straight part of the bowel although it’s not straight with at least three folds. Sometimes defined as the last 12 cm of the large bowel other consider it as the last 15 cm. Surgeons mark it s...
Financial Crisis and Health
The financial crisis has a dramatic impact on social life, since reduced or even non-existent incomes affect people’s well-being and push big parts of the population to poverty. The individuals’ financial status affects...
Role of tumor heterogeneity in drug resistance
Cancer is a leading cause of death in men worldwide and the major cause of cancer related death is drug resistance [1,2]. In past few years, scientists have established tumor heterogeneity as a phenomenon of critical imp...
The Role of Decavanadate in Anti-Tumour Activity
Decavanadate compounds were described to be involved in a variety of biological activities and responses such as anti-virus, anti-bacterial and anticancer. While the mechanisms of action of the anti-viral and anti-bacter...